Ocular Therapeutix, Inc. (OCUL)
7.13
-0.25
(-3.39%)
USD |
NASDAQ |
Oct 16, 09:54
Ocular Therapeutix SG&A Expense (TTM) : 135.74M for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 135.74M |
| March 31, 2026 | 124.38M |
| December 31, 2025 | 118.30M |
| September 30, 2025 | 113.12M |
| June 30, 2025 | 106.82M |
| March 31, 2025 | 108.41M |
| December 31, 2024 | 102.24M |
| September 30, 2024 | 94.07M |
| June 30, 2024 | 89.16M |
| March 31, 2024 | 78.86M |
| December 31, 2023 | 74.49M |
| September 30, 2023 | 76.10M |
| June 30, 2023 | 76.92M |
| March 31, 2023 | 75.49M |
| December 31, 2022 | 72.14M |
| September 30, 2022 | 69.93M |
| June 30, 2022 | 68.87M |
| March 31, 2022 | 67.94M |
| December 31, 2021 | 67.07M |
| September 30, 2021 | 63.79M |
| June 30, 2021 | 58.61M |
| March 31, 2021 | 52.92M |
| December 31, 2020 | 49.47M |
| September 30, 2020 | 48.78M |
| June 30, 2020 | 49.23M |
| Date | Value |
|---|---|
| March 31, 2020 | 50.21M |
| December 31, 2019 | 46.61M |
| September 30, 2019 | 41.33M |
| June 30, 2019 | 33.91M |
| March 31, 2019 | 26.94M |
| December 31, 2018 | 23.73M |
| September 30, 2018 | 21.50M |
| June 30, 2018 | 23.45M |
| March 31, 2018 | 28.69M |
| December 31, 2017 | 32.51M |
| September 30, 2017 | 32.86M |
| June 30, 2017 | 29.30M |
| March 31, 2017 | 23.21M |
| December 31, 2016 | 17.70M |
| September 30, 2016 | 15.91M |
| June 30, 2016 | 15.24M |
| March 31, 2016 | 14.05M |
| December 31, 2015 | 13.02M |
| September 30, 2015 | 12.16M |
| June 30, 2015 | 11.31M |
| March 31, 2015 | 9.774M |
| December 31, 2014 | 8.895M |
| September 30, 2014 | 6.606M |
| June 30, 2014 | 4.774M |
| March 31, 2014 | 3.043M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| EyePoint, Inc. | 55.41M |
| ANI Pharmaceuticals, Inc. | 324.76M |
| Eli Lilly & Co. | 12.24B |
| Corcept Therapeutics, Inc. | 556.47M |
| Veru, Inc. | 16.05M |